Hölzl B, Kraft H G, Wiebusch H, Sandhofer A, Patsch J, Sandhofer F, Paulweber B
First Department of Internal Medicine, General Hospital, Salzburg, Austria.
J Lipid Res. 2000 May;41(5):734-41.
Two novel mutations in the lipoprotein lipase (LPL) gene are described in an Austrian family: a splice site mutation in intron 1 (3 bp deletion of nucleotides -2 to -4) which results in skipping of exon 2, and a missense mutation in exon 5 which causes an asparagine for histidine substitution in codon 183 and complete loss of enzyme activity. A 5-year-old boy who exhibited all the clinical features of primary hyperchylomicronemia was a compound heterozygote for these two mutations. Nine other family members were investigated: seven were heterozygotes for the splice site mutation, one was a heterozygote for the missense mutation, and one had two wild-type alleles of the LPL gene. LPL activity in the post-heparin plasma of the heterozygotes was reduced to 49;-79% of the mean observed in normal individuals. Two of the heterozygotes had extremely high plasma triglyceride levels; in three of the other heterozygotes the plasma triglycerides were also elevated. As plasma triglycerides in carriers of one defective LPL allele can be normal or elevated, the heterozygotes of this family have been studied for a possible additional cause of the expression of hypertriglyceridemia in these subjects. Body mass index, insulin resistance, mutations in other candidate genes (Asn291Ser and Asp9Asn in the LPL gene, apoE isoforms, polymorphisms in the apoA-II gene and in the apoAI-CIII-AIV gene cluster, and in the IRS-1 gene) could be ruled out as possible factors contributing to the expression of hypertriglyceridemia in this family. A linkage analysis using the allelic marker D1S104 on chromosome 1q21;-q23 suggested that a gene in this region could play a role in the expression of hypertriglyceridemia in the heterozygous carriers of this family, but the evidence was not sufficiently strong to prove this assumption. Nevertheless, this polymorphic marker seems to be a good candidate for further studies.
在一个奥地利家庭中发现了脂蛋白脂肪酶(LPL)基因的两种新突变:内含子1的剪接位点突变(核苷酸-2至-4缺失3 bp),导致外显子2跳跃;外显子5的错义突变,导致密码子183处组氨酸被天冬酰胺取代,酶活性完全丧失。一名表现出原发性高乳糜微粒血症所有临床特征的5岁男孩是这两种突变的复合杂合子。对另外9名家庭成员进行了调查:7名是剪接位点突变的杂合子,1名是错义突变的杂合子,1名具有LPL基因的两个野生型等位基因。杂合子肝素后血浆中的LPL活性降至正常个体平均值的49%-79%。其中两名杂合子的血浆甘油三酯水平极高;其他三名杂合子的血浆甘油三酯也升高。由于携带一个缺陷LPL等位基因的个体血浆甘油三酯水平可能正常或升高,因此对这个家庭的杂合子进行了研究,以寻找这些受试者高甘油三酯血症表达的可能其他原因。体重指数、胰岛素抵抗、其他候选基因的突变(LPL基因中的Asn291Ser和Asp9Asn、载脂蛋白E异构体、载脂蛋白A-II基因和载脂蛋白AI-CIII-AIV基因簇以及胰岛素受体底物-1基因中的多态性)可被排除为该家庭高甘油三酯血症表达的可能因素。使用位于1q21-q23染色体上的等位基因标记D1S104进行的连锁分析表明,该区域的一个基因可能在这个家庭的杂合子携带者高甘油三酯血症的表达中起作用,但证据不够充分,无法证实这一假设。尽管如此,这个多态性标记似乎是进一步研究的良好候选对象。